Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4176914 | 0.91 | PDE4D (0.61) | PDE4DTSHRPOLBMAPK1KMT2A | |
| SCHEMBL14384610 | 0.89 | L3MBTL1 (0.50) | PDE4DKMT2AALDH1A1SIGMAR1MEP1B | |
| SCHEMBL4194071 | 0.84 | PDE4D (0.58) | PDE4DTSHRPOLBMAPK1KMT2A | |
| SCHEMBL7205749 | 0.84 | PDE4D (0.57) | PDE4DTSHRPOLBMAPK1KMT2A | |
| SCHEMBL4184591 | 0.83 | PDE4D (0.52) | PDE4DTSHRPOLBMAPK1KMT2A | |
| SCHEMBL4187978 | 0.83 | PDE4D (0.54) | PDE4DTSHRPOLBMAPK1KMT2A | |
| SCHEMBL23088243 | 0.82 | MAPT (0.61) | TSHRPOLBMAPK1KMT2AALDH1A1 | |
| SCHEMBL7204075 | 0.81 | PDE4D (0.55) | PDE4DTSHRPOLBMAPK1KMT2A | |
| SCHEMBL4191455 | 0.81 | PDE4D (0.58) | PDE4DTSHRPOLBMAPK1KMT2A | |
| SCHEMBL7204680 | 0.80 | TSHR (0.58) | PDE4DTSHRPOLBMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | claimed |
| EP-1976498-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-10-08 | — | — | EP | claimed |
| WO-2007127505-A2 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | WO | claimed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069302-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| EP-1976498-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007127505-A2 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF DISORDERS OF THE METABOLISM AND THE NERVOUS SYSTEM | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069302-A1 | CHEMICAL COMPOUNDS | TBXA2R, PDE4D, PDE4A | PDE4D 2/4885TSHR 576/4885POLB 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.